Anbio Biotechnology Class A Ordinary Shares - Asset Resilience Ratio
Anbio Biotechnology Class A Ordinary Shares (NNNN) has an Asset Resilience Ratio of 29.19% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read NNNN total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2023)
This chart shows how Anbio Biotechnology Class A Ordinary Shares's Asset Resilience Ratio has changed over time. See NNNN net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Anbio Biotechnology Class A Ordinary Shares's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see NNNN market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $9.49 Million | 29.19% |
| Total Liquid Assets | $9.49 Million | 29.19% |
Asset Resilience Insights
- Very High Liquidity: Anbio Biotechnology Class A Ordinary Shares maintains exceptional liquid asset reserves at 29.19% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Anbio Biotechnology Class A Ordinary Shares Industry Peers by Asset Resilience Ratio
Compare Anbio Biotechnology Class A Ordinary Shares's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087 |
Medical Instruments & Supplies | 9.08% |
|
Vizionfocus Inc.
TW:4771 |
Medical Instruments & Supplies | 5.07% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 4.42% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 51.82% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 6.36% |
|
Austco Healthcare Ltd
AU:AHC |
Medical Instruments & Supplies | 15.90% |
|
Trajan Group Holdings Ltd
AU:TRJ |
Medical Instruments & Supplies | 0.23% |
|
Osteopore Ltd
AU:OSX |
Medical Instruments & Supplies | 43.09% |
Annual Asset Resilience Ratio for Anbio Biotechnology Class A Ordinary Shares (2021–2023)
The table below shows the annual Asset Resilience Ratio data for Anbio Biotechnology Class A Ordinary Shares.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $15.81 Million | -- |
| 2022-12-31 | 11.22% | $1.57 Million | $13.96 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $4.92 Million | -- |
About Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcript… Read more